How acetaminophen affects opioid delivery to the brain
Increased CNS Opioid Exposure by an Acetaminophen-Induced Blood-Brain Barrier Mechanism
This study is looking at how acetaminophen affects the blood-brain barrier and how it might help opioids work better for pain relief, which could lead to safer ways to manage pain for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project ID | NIH-10839440 on NIH RePORTER |
What this research studies
This research investigates how acetaminophen (APAP) influences the blood-brain barrier (BBB) and its impact on opioid delivery to the central nervous system (CNS). The study focuses on the role of tight junction proteins, which are crucial for maintaining the integrity of the BBB, and how their expression changes in response to APAP and pain. By examining these mechanisms, the research aims to understand how APAP can increase the permeability of the BBB, potentially enhancing the effects of opioids and leading to both therapeutic benefits and risks. Patients may benefit from insights into safer pain management strategies involving opioids and acetaminophen.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who use acetaminophen and opioids for pain management.
Not a fit: Patients who do not use acetaminophen or opioids for pain relief may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved pain management strategies that enhance the effectiveness of opioids while minimizing risks of toxicity.
How similar studies have performed: While the specific approach of this research is novel, previous studies have shown that alterations in the blood-brain barrier can significantly affect drug delivery and efficacy.
Where this research is happening
Tucson, United States
- University of Arizona — Tucson, United States (Active)
Researchers
- Principal investigator: Davis, Thomas Paul — University of Arizona
- Study coordinator: Davis, Thomas Paul
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.